The FDA also updated the label for Ampyra, which is approved to help MS patients walk, to warn about the need to check kidney function before people start taking it, and every year after that.
(Reporting by Anna Yukhananov; Editing by Maureen Bavdek)
Copyright 2013 mojeNovosti.com
web developer: BTGcms